p53 reactivating small molecule PRIMA‑1<sup>MET</sup>/APR‑246 regulates genomic instability in MDA‑MB‑231 cells

Amirtharaj,Francis; Venkatesh,Goutham Hassan; Wojtas,Bartosz; Nawafleh,Hussam Hussein; Mahmood,Ayda Shah; Nizami,Zohra Nausheen; Khan,Munazza Samar; Thiery,Jerome; Chouaib,Salem

doi:10.3892/or.2022.8296

p53 reactivating small molecule PRIMA‑1^MET/APR‑246 regulates genomic instability in MDA‑MB‑231 cells

Authors:
- Francis Amirtharaj
- Goutham Hassan Venkatesh
- Bartosz Wojtas
- Hussam Hussein Nawafleh
- Ayda Shah Mahmood
- Zohra Nausheen Nizami
- Munazza Samar Khan
- Jerome Thiery
- Salem Chouaib
View Affiliations

Affiliations: Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman 4184, United Arab Emirates, Laboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, PAS, 02‑093 Warsaw, Poland, INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Faculty of Medicine, University Paris‑Saclay, F‑94805 Villejuif, France
Published online on: March 1, 2022 https://doi.org/10.3892/or.2022.8296
Article Number: 85

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pharmacological reactivation of tumor‑suppressor protein p53 has acted as a promising strategy for more than 50% of human cancers that carry a non‑functional mutant p53 (mutp53). p53 plays a critical role in preserving genomic integrity and DNA fidelity through numerous biological processes, including cell cycle arrest, DNA repair, senescence and apoptosis. By contrast, non‑functional mutp53 compromises the aforementioned genome stabilizing mechanisms through gain of function, thereby increasing genomic instability in human cancers. Restoring the functional activity of p53 using both genetic and pharmacological approaches has gained prominence in targeting p53‑mutated tumors. Thus, the present study aimed to investigate the reactivation of p53 in DNA repair mechanisms and the maintenance of genomic stability using PRIMA‑1^MET/APR‑246 small molecules, in both MDA‑MB‑231 and MCF‑7 breast cancer cell lines, which carry mutp53 and wild‑type p53, respectively. Results of the present study revealed that reactivation of p53 through APR‑246 led to an increase in the functional activity of DNA repair. Prolonged treatment of MDA‑MB‑231 cells with APR‑246 in the presence of cisplatin led to a reduction in mutational accumulation, compared with cells treated with cisplatin alone. These findings demonstrated that APR‑246 may act as a promising small molecule to control the genomic instability in p53‑mutated tumors.

View Figures

View References

1	Rieber M and Strasberg-Rieber M: Hypoxia, Mn-SOD and H₂O₂ regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells. Biochem Pharmacol. 84:1563–1570. 2012. View Article : Google Scholar : PubMed/NCBI
2	Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, et al: Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 145:571–583. 2011. View Article : Google Scholar : PubMed/NCBI
3	Gupta A, Shah K, Oza MJ and Behl T: Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Biomed Pharmacother. 109:484–492. 2019. View Article : Google Scholar : PubMed/NCBI
4	Labuschagne CF, Zani F and Vousden KH: Control of metabolism by p53-Cancer and beyond. Biochim Biophys Acta Rev Cancer. 1870:32–42. 2018. View Article : Google Scholar : PubMed/NCBI
5	Nakayama M, Hong CP, Oshima H, Sakai E, Kim SJ and Oshima M: Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties. Nat Commun. 11:23332020. View Article : Google Scholar : PubMed/NCBI
6	Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, et al: COSMIC: Somatic cancer genetics at high-resolution. Nucleic Acids Res. 45((D1)): D777–D783. 2017. View Article : Google Scholar : PubMed/NCBI
7	Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J and Olivier M: TP53 Variations in human cancers: New lessons from the IARC TP53 database and genomics data. Hum Mutat. 37:865–876. 2016. View Article : Google Scholar : PubMed/NCBI
8	Hwang LA, Phang BH, Liew OW, Iqbal J, Koh XH, Koh XY, Othman R, Xue Y, Richards AM, Lane DP and Sabapathy K: Monoclonal antibodies against specific p53 hotspot mutants as potential tools for precision medicine. Cell Rep. 22:299–312. 2018. View Article : Google Scholar : PubMed/NCBI
9	van Oijen MG and Slootweg PJ: Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res. 6:2138–2145. 2000.PubMed/NCBI
10	Sears CR and Turchi JJ: Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathways. J Biol Chem. 287:24263–24272. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bykov VJ and Wiman KG: Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett. 588:2622–2627. 2014. View Article : Google Scholar : PubMed/NCBI
12	Liu DS, Read M, Cullinane C, Azar WJ, Fennell CM, Montgomery KG, Haupt S, Haupt Y, Wiman KG, Duong CP, et al: APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut. 64:1506–1516. 2015. View Article : Google Scholar : PubMed/NCBI
13	Russo D, Ottaggio L, Foggetti G, Masini M, Masiello P, Fronza G and Menichini P: PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53. Biochim Biophys Acta. 1833:1904–1913. 2013. View Article : Google Scholar : PubMed/NCBI
14	Perdrix A, Najem A, Saussez S, Awada A, Journe F, Ghanem G and Krayem M: PRIMA-1 and PRIMA-1^Met (APR-246): From mutant/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies. Cancers (Basel). 9:1722017. View Article : Google Scholar : PubMed/NCBI
15	Zhang Q, Bykov VJN, Wiman KG and Zawacka-Pankau J: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis. 9:4392018. View Article : Google Scholar : PubMed/NCBI
16	Muller PA and Vousden KH: Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
17	Chollat-Namy M, Ben Safta-Saadoun T, Haferssas D, Meurice G, Chouaib S and Thiery J: The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy. Cell Death Dis. 10:6952019. View Article : Google Scholar : PubMed/NCBI
18	Hansen SN, Ehlers NS, Zhu S, Thomsen MB, Nielsen RL, Liu D, Wang G, Hou Y, Zhang X, Xu X, et al: The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. BMC Genomics. 17:4422016. View Article : Google Scholar : PubMed/NCBI
19	Olive PL and Banath JP: The comet assay: A method to measure DNA damage in individual cells. Nat Protoc. 1:23–29. 2006. View Article : Google Scholar : PubMed/NCBI
20	Gyori BM, Venkatachalam G, Thiagarajan PS, Hsu D and Clement MV: OpenComet: An automated tool for comet assay image analysis. Redox Biol. 2:457–465. 2014. View Article : Google Scholar : PubMed/NCBI
21	Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L and Wilson RK: VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22:568–576. 2012. View Article : Google Scholar : PubMed/NCBI
22	McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P and Cunningham F: The ensembl variant effect predictor. Genome Biol. 17:1222016. View Article : Google Scholar : PubMed/NCBI
23	Mayakonda A, Lin DC, Assenov Y, Plass C and Koeffler HP: Maftools: Efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28:1747–1756. 2018. View Article : Google Scholar : PubMed/NCBI
24	Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A and Bonner WM: Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol. 81:123–129. 2003. View Article : Google Scholar : PubMed/NCBI
25	Berkers CR, Maddocks OD, Cheung EC, Mor I and Vousden KH: Metabolic regulation by p53 family members. Cell Metab. 18:617–633. 2013. View Article : Google Scholar : PubMed/NCBI
26	Williams AB and Schumacher B: p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med. 6:a0260702016. View Article : Google Scholar : PubMed/NCBI
27	Yu X, Vazquez A, Levine AJ and Carpizo DR: Allele-specific p53 mutant reactivation. Cancer Cell. 21:614–625. 2012. View Article : Google Scholar : PubMed/NCBI
28	Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE and Hyder SM: Targeting mutant p53 protein and the tumor vasculature: An effective combination therapy for advanced breast tumors. Breast Cancer Res Treat. 125:407–420. 2011. View Article : Google Scholar : PubMed/NCBI
29	Liang Y, Besch-Williford C, Cook MT, Belenchia A, Brekken RA and Hyder SM: APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice. Breast Cancer (Dove Med Press). 11:249–259. 2019.PubMed/NCBI
30	Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG and Bykov VJ: PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 15:376–388. 2009. View Article : Google Scholar : PubMed/NCBI
31	Li XL, Zhou J, Chan ZL, Chooi JY, Chen ZR and Chng WJ: PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms. Oncotarget. 6:36689–36699. 2015. View Article : Google Scholar : PubMed/NCBI
32	Li XL, Zhou J, Xia CJ, Min H, Lu ZK and Chen ZR: PRIMA-1met induces autophagy in colorectal cancer cells through upregulation of the mTOR/AMPK-ULK1-Vps34 signaling cascade. Oncol Rep. 45:862021. View Article : Google Scholar : PubMed/NCBI
33	Makhale A, Nanayakkara D, Raninga P, Khanna KK and Kalimutho M: CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancer. Int J Mol Sci. 22:57822021. View Article : Google Scholar : PubMed/NCBI
34	Synnott NC, Madden SF, Bykov VJN, Crown J, Wiman KG and Duffy MJ: The mutant p53-targeting compound APR-246 Induces ROS-modulating genes in breast cancer cells. Transl Oncol. 11:1343–1349. 2018. View Article : Google Scholar : PubMed/NCBI
35	Mantovani F, Collavin L and Del Sal G: Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 26:199–212. 2019. View Article : Google Scholar : PubMed/NCBI
36	Srinivas US, Tan BWQ, Vellayappan BA and Jeyasekharan AD: ROS and the DNA damage response in cancer. Redox Biol. 25:1010842019. View Article : Google Scholar : PubMed/NCBI
37	Khanna A: DNA damage in cancer therapeutics: A boon or a curse? Cancer Res. 75:2133–2138. 2015. View Article : Google Scholar : PubMed/NCBI
38	Garcia-de Teresa B, Hernandez-Gomez M and Frias S: DNA Damage as a driver for growth delay: Chromosome instability syndromes with intrauterine growth retardation. Biomed Res Int. 2017:81938922017. View Article : Google Scholar : PubMed/NCBI
39	Eischen CM: Genome stability requires p53. Cold Spring Harb Perspect Med. 6:a0260962016. View Article : Google Scholar : PubMed/NCBI
40	Zhu G, Pan C, Bei JX, Li B, Liang C, Xu Y and Fu X: Mutant p53 in Cancer progression and targeted therapies. Front Oncol. 10:5951872020. View Article : Google Scholar : PubMed/NCBI
41	Watanabe N, Okochi E, Mochizuki M, Sugimura T and Ushijima T: The presence of single nucleotide instability in human breast cancer cell lines. Cancer Res. 61:7739–7742. 2001.PubMed/NCBI